AR088380A1 - Formulaciones de etanercept estabilizadas con cloruro de sodio - Google Patents
Formulaciones de etanercept estabilizadas con cloruro de sodioInfo
- Publication number
- AR088380A1 AR088380A1 ARP120103886A ARP120103886A AR088380A1 AR 088380 A1 AR088380 A1 AR 088380A1 AR P120103886 A ARP120103886 A AR P120103886A AR P120103886 A ARP120103886 A AR P120103886A AR 088380 A1 AR088380 A1 AR 088380A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- weight
- sodium chloride
- peak
- etanercept
- Prior art date
Links
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title abstract 16
- 239000000203 mixture Substances 0.000 title abstract 16
- 239000011780 sodium chloride Substances 0.000 title abstract 8
- 108010008165 Etanercept Proteins 0.000 title abstract 7
- 229960000403 etanercept Drugs 0.000 title abstract 6
- 239000004475 Arginine Substances 0.000 abstract 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 4
- 229930006000 Sucrose Natural products 0.000 abstract 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 4
- 239000005720 sucrose Substances 0.000 abstract 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000178 monomer Substances 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 229940073621 enbrel Drugs 0.000 abstract 1
- 238000013467 fragmentation Methods 0.000 abstract 1
- 238000006062 fragmentation reaction Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 239000008181 tonicity modifier Substances 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548518P | 2011-10-18 | 2011-10-18 | |
| US201261669480P | 2012-07-09 | 2012-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088380A1 true AR088380A1 (es) | 2014-05-28 |
Family
ID=48136153
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103886A AR088380A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con cloruro de sodio |
| ARP120103887A AR088381A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con meglumina |
| ARP120103884A AR088460A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con aminoacidos |
| ARP120103885A AR088379A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con iones metalicos |
| ARP120103889A AR088383A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles |
| ARP120103888A AR088382A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con xilitol |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103887A AR088381A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con meglumina |
| ARP120103884A AR088460A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con aminoacidos |
| ARP120103885A AR088379A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con iones metalicos |
| ARP120103889A AR088383A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles |
| ARP120103888A AR088382A1 (es) | 2011-10-18 | 2012-10-18 | Formulaciones de etanercept estabilizadas con xilitol |
Country Status (28)
| Country | Link |
|---|---|
| US (21) | US9801942B2 (en:Method) |
| EP (6) | EP2768531A4 (en:Method) |
| JP (6) | JP6104922B2 (en:Method) |
| KR (7) | KR20140079491A (en:Method) |
| CN (6) | CN104010657A (en:Method) |
| AR (6) | AR088380A1 (en:Method) |
| AU (6) | AU2012326168B2 (en:Method) |
| BR (6) | BR112014009031A2 (en:Method) |
| CA (6) | CA2851635A1 (en:Method) |
| CY (1) | CY1121843T1 (en:Method) |
| DK (1) | DK2768525T3 (en:Method) |
| EA (6) | EA026410B1 (en:Method) |
| ES (1) | ES2734070T3 (en:Method) |
| HK (3) | HK1200721A1 (en:Method) |
| HR (1) | HRP20191215T1 (en:Method) |
| HU (1) | HUE045624T2 (en:Method) |
| IL (6) | IL231824A0 (en:Method) |
| IN (3) | IN2014CN02592A (en:Method) |
| LT (1) | LT2768525T (en:Method) |
| MX (7) | MX2014004725A (en:Method) |
| PL (1) | PL2768525T3 (en:Method) |
| PT (1) | PT2768525T (en:Method) |
| RS (1) | RS59179B1 (en:Method) |
| SG (6) | SG11201401562RA (en:Method) |
| SI (1) | SI2768525T1 (en:Method) |
| SM (1) | SMT201900422T1 (en:Method) |
| TW (6) | TWI644681B (en:Method) |
| WO (6) | WO2013059412A1 (en:Method) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| TWI644681B (zh) * | 2011-10-18 | 2018-12-21 | 美商柯赫勒斯生物科學有限公司 | 用金屬離子穩定化之依那西普調配物 |
| US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
| HK1209343A1 (en) | 2012-07-09 | 2016-04-01 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| RS57013B1 (sr) | 2012-09-11 | 2018-05-31 | Coherus Biosciences Inc | Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom |
| US20160106844A1 (en) * | 2013-05-02 | 2016-04-21 | Mabxience, S.A. | Alternative formulations for tnfr: fc fusion polypeptides |
| WO2015056613A1 (ja) * | 2013-10-15 | 2015-04-23 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 安定化されたポリペプチド水性製剤 |
| KR102109053B1 (ko) * | 2013-10-24 | 2020-05-13 | 아스트라제네카 아베 | 안정한 수성 항체 제제 |
| BR112016011224A2 (pt) * | 2013-11-29 | 2017-09-19 | Ares Trading Sa | Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc |
| IS3008B (is) * | 2014-05-14 | 2018-12-15 | Calor ehf | Stöðgandi lausnir fyrir prótín og peptíð |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
| AU2015371381A1 (en) * | 2014-12-22 | 2017-07-20 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3236942A1 (en) * | 2014-12-23 | 2017-11-01 | Drug Discovery Laboratory AS | Protein compositions and use thereof |
| WO2016108569A1 (ko) * | 2014-12-31 | 2016-07-07 | 주식회사 엘지생명과학 | 목적하는 함량으로 불순물을 포함하는 tnfr-fc 융합 단백질의 제조방법 |
| CN104694355B (zh) * | 2015-03-20 | 2016-09-28 | 吉林大学 | 葛根护肝保健酒及其制备方法 |
| MX389818B (es) * | 2015-08-13 | 2025-03-20 | Landsteiner Scient S A De C V | Composicion de estabilidad mejorada de etanercept. |
| JP5938762B1 (ja) * | 2015-09-01 | 2016-06-22 | 日揮株式会社 | マイクロカプセル製剤及びその製造方法 |
| CN105748414A (zh) * | 2016-03-02 | 2016-07-13 | 张光泉 | 抗感染米卡芬净冻干组合物及其制备方法 |
| JPWO2017179683A1 (ja) * | 2016-04-15 | 2019-02-21 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ミカファンギンの安定化された医薬組成物 |
| CN109982685B (zh) * | 2016-10-21 | 2022-03-11 | 美国安进公司 | 药物配制品及其制备方法 |
| WO2018080196A2 (ko) | 2016-10-28 | 2018-05-03 | (주)셀트리온 | 안정한 약제학적 제제 |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| MX2017013995A (es) * | 2017-10-31 | 2019-05-01 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina de fusion. |
| US20220071901A1 (en) * | 2017-11-30 | 2022-03-10 | Bio-Thera Solutions, Ltd. | A liquid formulation of humanized antibody for treating il-6-mediated diseases |
| JP7692699B2 (ja) * | 2017-12-22 | 2025-06-16 | サムスン バイオエピス カンパニー リミテッド | Ｖｅｇｆアンタゴニストを含む液体組成物 |
| CA3042126A1 (en) | 2018-05-03 | 2019-11-03 | Michael A. Portman | Methods of treating kawasaki disease |
| CN111228225B (zh) * | 2018-11-28 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂 |
| GB201911461D0 (en) * | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| EP4065166A4 (en) * | 2019-11-26 | 2023-12-20 | Comera Life Sciences, Inc. | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS |
| EP4294371A1 (en) | 2021-02-17 | 2023-12-27 | Arecor Limited | Aqueous composition of an engineered protein construct comprising an fc domain |
| CN114788809B (zh) * | 2022-01-25 | 2023-04-14 | 江苏广承药业有限公司 | 一种氯雷他定液体制剂 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| JPH07504203A (ja) | 1992-09-15 | 1995-05-11 | イミュネックス・コーポレーション | 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法 |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| US6677326B2 (en) * | 1999-03-15 | 2004-01-13 | Arakis, Ltd. | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
| CA2366785C (en) * | 1999-04-19 | 2012-02-07 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| EP1261364A1 (en) | 2000-02-10 | 2002-12-04 | Wyeth | Method of treating or inhibiting cellular injury or cell death |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| US6936437B2 (en) * | 2001-02-23 | 2005-08-30 | Lucia Irene Gonzalez-Villasenor | Methods and compositions for production of recombinant peptides |
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| KR20050105486A (ko) * | 2003-02-28 | 2005-11-04 | 아레스 트레이딩 에스.에이. | 종양괴사인자-결합 단백질의 액상 제제 |
| EP1607103A1 (en) | 2003-03-20 | 2005-12-21 | Eisai Co., Ltd. | Concomitant drug as therapeutic agent for inflammatory bowel disease |
| WO2005012353A1 (en) | 2003-08-01 | 2005-02-10 | Amgen Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
| NZ546347A (en) | 2003-10-14 | 2009-11-27 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
| WO2005082377A1 (ja) | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
| WO2005095578A1 (en) | 2004-03-05 | 2005-10-13 | Dsm Ip Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| BRPI0611901A2 (pt) * | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| CN101378773B (zh) | 2005-12-20 | 2013-03-13 | 布里斯托尔—迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| AU2006330858A1 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| KR20080098504A (ko) | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
| EP1996076A2 (en) | 2006-03-21 | 2008-12-03 | Eugen Oetringer | Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property |
| US20080003220A1 (en) | 2006-04-21 | 2008-01-03 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| CN103540575A (zh) * | 2006-08-01 | 2014-01-29 | 奇尼塔二有限责任公司 | 医药制造方法 |
| EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| MX2009003982A (es) | 2006-10-20 | 2009-04-27 | Amgen Inc | Formulaciones de polipeptido estables. |
| US8192951B2 (en) | 2006-11-03 | 2012-06-05 | Wyeth Llc | Glycolysis-inhibiting substances in cell culture |
| CA2790018C (en) | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
| ES2728912T3 (es) | 2007-03-02 | 2019-10-29 | Wyeth Llc | Uso de cobre y glutamato en cultivo celular para la producción de polipéptidos |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| AU2008266051B2 (en) | 2007-06-14 | 2014-07-31 | Biogen Ma Inc. | Antibody formulations |
| TWI629064B (zh) | 2007-11-30 | 2018-07-11 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| SG2013054218A (en) * | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| WO2009111347A1 (en) | 2008-02-29 | 2009-09-11 | Biogen Idec Ma Inc. | Purified immunoglobulin fusion proteins and methods of their purification |
| WO2011015926A1 (en) | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
| BR112012002974B1 (pt) | 2009-08-11 | 2022-06-07 | Genentech, Inc | Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo |
| US20120208986A1 (en) | 2009-10-20 | 2012-08-16 | Wenger Marc D | Use of mixed mode chromatography for the capture and purification of basic antibody products |
| US20130052195A1 (en) | 2009-12-23 | 2013-02-28 | Emergent Product Development Seattle,LLC | Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof |
| PL2563904T3 (pl) | 2010-04-26 | 2015-06-30 | Novartis Ag | Udoskonalona pożywka do hodowli komórkowej |
| WO2011141926A2 (en) * | 2010-05-10 | 2011-11-17 | Intas Biopharmaceuticals Limited | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin |
| WO2012013980A1 (en) | 2010-07-30 | 2012-02-02 | Arecor Limited | Stabilized aqueous antibody compositions |
| WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| KR20130101034A (ko) | 2010-08-31 | 2013-09-12 | 프리슬랜드 브랜즈 비브이 | 진핵 세포를 위한 배양 배지 |
| RU2610667C2 (ru) | 2010-10-11 | 2017-02-14 | Эббви Бахамаз Лтд., | Способ очистки белков |
| CA2833427C (en) * | 2011-04-20 | 2019-09-24 | Sandoz Ag | Stable pharmaceutical liquid formulations of the fusion protein tnfr:fc |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US20140142055A1 (en) | 2011-06-29 | 2014-05-22 | Insite Vision Corporation | Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence |
| KR102358951B1 (ko) | 2011-07-01 | 2022-02-08 | 암젠 인크 | 포유동물 세포 배양 |
| WO2013006454A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
| US9781540B2 (en) * | 2011-07-07 | 2017-10-03 | Qualcomm Incorporated | Application relevance determination based on social context |
| KR20140043934A (ko) | 2011-07-08 | 2014-04-11 | 머크 샤프 앤드 돔 코포레이션 | Ｆｃ-융합 단백질의 정제 방법 |
| KR101454316B1 (ko) | 2011-08-17 | 2014-10-27 | 한화케미칼 주식회사 | 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법 |
| TWI644681B (zh) * | 2011-10-18 | 2018-12-21 | 美商柯赫勒斯生物科學有限公司 | 用金屬離子穩定化之依那西普調配物 |
| RS57013B1 (sr) | 2012-09-11 | 2018-05-31 | Coherus Biosciences Inc | Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom |
-
2012
- 2012-10-18 TW TW101138565A patent/TWI644681B/zh not_active IP Right Cessation
- 2012-10-18 US US13/654,770 patent/US9801942B2/en not_active Expired - Fee Related
- 2012-10-18 MX MX2014004725A patent/MX2014004725A/es unknown
- 2012-10-18 EA EA201490801A patent/EA026410B1/ru not_active IP Right Cessation
- 2012-10-18 AR ARP120103886A patent/AR088380A1/es unknown
- 2012-10-18 LT LTEP12842352.2T patent/LT2768525T/lt unknown
- 2012-10-18 MX MX2014004726A patent/MX367054B/es active IP Right Grant
- 2012-10-18 WO PCT/US2012/060748 patent/WO2013059412A1/en not_active Ceased
- 2012-10-18 IN IN2592CHN2014 patent/IN2014CN02592A/en unknown
- 2012-10-18 TW TW101138567A patent/TWI595883B/zh not_active IP Right Cessation
- 2012-10-18 CN CN201280062748.3A patent/CN104010657A/zh active Pending
- 2012-10-18 KR KR1020147013306A patent/KR20140079491A/ko not_active Withdrawn
- 2012-10-18 CA CA2851635A patent/CA2851635A1/en not_active Abandoned
- 2012-10-18 CA CA2851646A patent/CA2851646A1/en not_active Abandoned
- 2012-10-18 BR BR112014009031A patent/BR112014009031A2/pt not_active Application Discontinuation
- 2012-10-18 HK HK15101257.9A patent/HK1200721A1/xx unknown
- 2012-10-18 SI SI201231635T patent/SI2768525T1/sl unknown
- 2012-10-18 SG SG11201401562RA patent/SG11201401562RA/en unknown
- 2012-10-18 US US13/654,735 patent/US10293049B2/en not_active Expired - Fee Related
- 2012-10-18 PT PT12842352T patent/PT2768525T/pt unknown
- 2012-10-18 JP JP2014537218A patent/JP6104922B2/ja not_active Expired - Fee Related
- 2012-10-18 AR ARP120103887A patent/AR088381A1/es unknown
- 2012-10-18 KR KR1020147013305A patent/KR20140091707A/ko not_active Withdrawn
- 2012-10-18 TW TW101138564A patent/TW201325608A/zh unknown
- 2012-10-18 PL PL12842352T patent/PL2768525T3/pl unknown
- 2012-10-18 TW TW101138566A patent/TWI619504B/zh not_active IP Right Cessation
- 2012-10-18 WO PCT/US2012/060741 patent/WO2013059407A1/en not_active Ceased
- 2012-10-18 MX MX2014004728A patent/MX2014004728A/es unknown
- 2012-10-18 SG SG11201401517VA patent/SG11201401517VA/en unknown
- 2012-10-18 TW TW101138561A patent/TW201325607A/zh unknown
- 2012-10-18 BR BR112014009131A patent/BR112014009131A8/pt not_active IP Right Cessation
- 2012-10-18 JP JP2014537223A patent/JP6220789B2/ja not_active Expired - Fee Related
- 2012-10-18 AR ARP120103884A patent/AR088460A1/es unknown
- 2012-10-18 MX MX2014004733A patent/MX2014004733A/es unknown
- 2012-10-18 EA EA201490802A patent/EA028520B1/ru not_active IP Right Cessation
- 2012-10-18 EP EP12841505.6A patent/EP2768531A4/en not_active Withdrawn
- 2012-10-18 KR KR1020147013301A patent/KR20140091705A/ko not_active Withdrawn
- 2012-10-18 HU HUE12842352A patent/HUE045624T2/hu unknown
- 2012-10-18 EP EP12841522.1A patent/EP2768532A4/en not_active Withdrawn
- 2012-10-18 BR BR112014009146A patent/BR112014009146A8/pt not_active IP Right Cessation
- 2012-10-18 EA EA201490804A patent/EA201490804A1/ru unknown
- 2012-10-18 KR KR1020147013304A patent/KR20140091706A/ko not_active Withdrawn
- 2012-10-18 ES ES12842352T patent/ES2734070T3/es active Active
- 2012-10-18 AU AU2012326168A patent/AU2012326168B2/en not_active Ceased
- 2012-10-18 BR BR112014009073A patent/BR112014009073A2/pt not_active IP Right Cessation
- 2012-10-18 CN CN201280062739.4A patent/CN103998061A/zh active Pending
- 2012-10-18 AU AU2012326080A patent/AU2012326080B2/en not_active Ceased
- 2012-10-18 MX MX2014004732A patent/MX2014004732A/es unknown
- 2012-10-18 AU AU2012326082A patent/AU2012326082B2/en not_active Ceased
- 2012-10-18 WO PCT/US2012/060745 patent/WO2013059410A1/en not_active Ceased
- 2012-10-18 EP EP12842312.6A patent/EP2768535A4/en not_active Withdrawn
- 2012-10-18 CN CN201280062747.9A patent/CN104010654B/zh not_active Expired - Fee Related
- 2012-10-18 RS RSP20190864 patent/RS59179B1/sr unknown
- 2012-10-18 SG SG11201401519RA patent/SG11201401519RA/en unknown
- 2012-10-18 HR HRP20191215TT patent/HRP20191215T1/hr unknown
- 2012-10-18 AR ARP120103885A patent/AR088379A1/es unknown
- 2012-10-18 CA CA2851651A patent/CA2851651A1/en not_active Abandoned
- 2012-10-18 AU AU2012326084A patent/AU2012326084B2/en not_active Ceased
- 2012-10-18 IN IN2527CHN2014 patent/IN2014CN02527A/en unknown
- 2012-10-18 SG SG11201401563SA patent/SG11201401563SA/en unknown
- 2012-10-18 IN IN2591CHN2014 patent/IN2014CN02591A/en unknown
- 2012-10-18 TW TW101138560A patent/TW201325606A/zh unknown
- 2012-10-18 AU AU2012326170A patent/AU2012326170B2/en not_active Ceased
- 2012-10-18 SM SM20190422T patent/SMT201900422T1/it unknown
- 2012-10-18 AR ARP120103889A patent/AR088383A1/es unknown
- 2012-10-18 KR KR1020207000845A patent/KR102163150B1/ko not_active Expired - Fee Related
- 2012-10-18 EA EA201490815A patent/EA025267B1/ru not_active IP Right Cessation
- 2012-10-18 KR KR1020147013303A patent/KR102068462B1/ko not_active Expired - Fee Related
- 2012-10-18 CA CA2851639A patent/CA2851639C/en active Active
- 2012-10-18 JP JP2014537222A patent/JP6113176B2/ja not_active Expired - Fee Related
- 2012-10-18 DK DK12842352.2T patent/DK2768525T3/da active
- 2012-10-18 JP JP2014537219A patent/JP6110393B2/ja not_active Expired - Fee Related
- 2012-10-18 KR KR1020147013302A patent/KR20140083037A/ko not_active Withdrawn
- 2012-10-18 AR ARP120103888A patent/AR088382A1/es unknown
- 2012-10-18 CN CN201280062758.7A patent/CN104011073B/zh not_active Expired - Fee Related
- 2012-10-18 WO PCT/US2012/060738 patent/WO2013059405A1/en not_active Ceased
- 2012-10-18 AU AU2012326171A patent/AU2012326171B2/en not_active Ceased
- 2012-10-18 SG SG11201401567YA patent/SG11201401567YA/en unknown
- 2012-10-18 EP EP12841765.6A patent/EP2768533A4/en not_active Withdrawn
- 2012-10-18 JP JP2014537221A patent/JP6199298B2/ja not_active Expired - Fee Related
- 2012-10-18 BR BR112014009087A patent/BR112014009087A2/pt not_active IP Right Cessation
- 2012-10-18 EA EA201490803A patent/EA027325B1/ru not_active IP Right Cessation
- 2012-10-18 US US13/654,919 patent/US9393305B2/en not_active Expired - Fee Related
- 2012-10-18 EA EA201490817A patent/EA025663B1/ru unknown
- 2012-10-18 EP EP12842226.8A patent/EP2768854A4/en not_active Withdrawn
- 2012-10-18 CA CA2851642A patent/CA2851642A1/en not_active Abandoned
- 2012-10-18 SG SG11201401576WA patent/SG11201401576WA/en unknown
- 2012-10-18 CN CN201280062761.9A patent/CN104010658A/zh active Pending
- 2012-10-18 HK HK15101253.3A patent/HK1200718A1/xx unknown
- 2012-10-18 WO PCT/US2012/060743 patent/WO2013059408A1/en not_active Ceased
- 2012-10-18 US US13/654,950 patent/US9302002B2/en not_active Expired - Fee Related
- 2012-10-18 EP EP12842352.2A patent/EP2768525B1/en active Active
- 2012-10-18 CA CA2851628A patent/CA2851628A1/en not_active Abandoned
- 2012-10-18 HK HK15101258.8A patent/HK1200722A1/xx unknown
- 2012-10-18 WO PCT/US2012/060739 patent/WO2013059406A1/en not_active Ceased
- 2012-10-18 JP JP2014537220A patent/JP6220788B2/ja not_active Expired - Fee Related
- 2012-10-18 CN CN201280062418.4A patent/CN103998060B/zh not_active Expired - Fee Related
- 2012-10-18 BR BR112014009022A patent/BR112014009022A2/pt not_active IP Right Cessation
- 2012-10-18 MX MX2014004734A patent/MX2014004734A/es unknown
-
2014
- 2014-03-31 IL IL231824A patent/IL231824A0/en unknown
- 2014-03-31 IL IL231825A patent/IL231825A0/en unknown
- 2014-03-31 IL IL231827A patent/IL231827A0/en unknown
- 2014-03-31 IL IL231826A patent/IL231826A0/en unknown
- 2014-03-31 IL IL231828A patent/IL231828A0/en unknown
- 2014-03-31 IL IL231829A patent/IL231829A0/en unknown
- 2014-04-16 MX MX2019009176A patent/MX2019009176A/es unknown
-
2016
- 2016-03-23 US US15/078,755 patent/US9943601B2/en active Active
- 2016-07-13 US US15/209,484 patent/US9770510B2/en not_active Expired - Fee Related
-
2017
- 2017-09-26 US US15/716,005 patent/US10213508B2/en not_active Expired - Fee Related
- 2017-10-31 US US15/799,798 patent/US11135267B2/en not_active Expired - Fee Related
-
2018
- 2018-03-09 US US15/917,333 patent/US10376588B2/en not_active Expired - Fee Related
-
2019
- 2019-02-25 US US16/284,265 patent/US10772963B2/en not_active Expired - Fee Related
- 2019-03-21 US US16/360,196 patent/US11129876B2/en not_active Expired - Fee Related
- 2019-06-14 US US16/441,088 patent/US20190290765A1/en not_active Abandoned
- 2019-06-14 US US16/441,110 patent/US10987405B2/en not_active Expired - Fee Related
- 2019-06-14 US US16/441,095 patent/US10980885B2/en not_active Expired - Fee Related
- 2019-06-14 US US16/441,092 patent/US10980884B2/en not_active Expired - Fee Related
- 2019-06-14 US US16/441,103 patent/US10888619B2/en not_active Expired - Fee Related
- 2019-06-25 US US16/451,732 patent/US20190328875A1/en not_active Abandoned
- 2019-06-26 US US16/453,041 patent/US20190314498A1/en not_active Abandoned
- 2019-06-26 US US16/453,154 patent/US20190314499A1/en not_active Abandoned
- 2019-06-27 US US16/454,817 patent/US20190314500A1/en not_active Abandoned
- 2019-07-03 CY CY20191100709T patent/CY1121843T1/el unknown
-
2020
- 2020-09-14 US US17/019,722 patent/US20200405865A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088380A1 (es) | Formulaciones de etanercept estabilizadas con cloruro de sodio | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| AR089673A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| PE20120342A1 (es) | Formulacion de anticuerpo | |
| BR112015008186A2 (pt) | formulação de um anticorpo estável e de baixa viscosidade | |
| RU2012153786A (ru) | Стабильные многодозовые композиции, содержащие антитело и консервант | |
| PE20191815A1 (es) | Formulaciones acuosas estables de adalimumab | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
| EA201200475A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| BR112012018023A2 (pt) | formulações líquidas que contêm anticorpo estabilizado. | |
| ME02818B (me) | Stab ilna tečna formulacija amg 416 (velkalcetida) | |
| MX2014009660A (es) | Formulacion de anticuerpo anti-selectina p. | |
| BR112015006464A2 (pt) | composição farmacêutica compreendendo rebamipida | |
| BR112012033052A2 (pt) | suspensões oftálmicas tópicas contendo tobramicin e dexametasona | |
| AR098386A1 (es) | Formulación para gonadotropinas | |
| FI3554474T3 (fi) | Mikafungiinikoostumuksia | |
| AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
| BR112015014180A2 (pt) | composições de gel | |
| RU2014129871A (ru) | Состав для криоконсервации сперматозоидов | |
| AR091707A1 (es) | Formulaciones estabilizadas de etanercept | |
| RU2015117254A (ru) | Стабильная инъекционная фармацевтическая композиция эпинефрина или его солей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |